Expression of intracellular interleukin-17 in systemic lupus erythematosus patients
Benha Medical Journal, Year 2016, Volume 33, Issue 1 [p. 14-18] DOI: 10.4103/1110-208X.194382 • 2016
Publication Information
Authors
Eman R Abd El-Gwad, Fatemah A Elshabacy, Neveen A Abdul-Hafeez, Seham G AmeenBenha Medical Journal, Year 2016, Volume 33, Issue 1 [p. 14-18]DOI: 10.4103/1110-208X.194
Keywords
Not Available
Journal
Benha Medical Journal, Year 2016, Volume 33, Issue 1 [p. 14-18] DOI: 10.4103/1110-208X.194382
Publisher
Wolter-Klawer Medknow
Volume
33
Issue
1
Pages
14-18
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background Many significant evidences implicate interleukin-17 (IL-17) in inflammation, autoimmunity, and defense against some bacteria. One of the chronic autoimmune diseases in which IL-17 might be involved in is systemic lupus erythematosus (SLE). Evidences have identified IL-17 as a key player in the pathogenesis of SLE.
Aim of the study The aim of this study was to verify how IL-17 was involved in the immune response in patients with SLE.
Patients and methods Forty diagnosed cases of SLE and 20 apparently healthy individuals serving as a control group were recruited for this case–control study from Benha University Hospital and Benha Teaching Hospital. Sterile peripheral blood samples were collected from the study group and the percentage of IL-17 expressing T-cell subpopulation was determined by using flow cytometry.
Results After suitable statistical analysis, our results showed a high percentage of intracellular IL-17 in SLE patients and a high statistical increase in the intensity of IL-17 in CD3+, CD4+, and CD8+ T cells in SLE cases when compared with the control group
Staff Members - Benha University